Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2024

Open Access 01-12-2024 | Liver Transplantation | Research

NR1H4 disease: rapidly progressing neonatal intrahepatic cholestasis and early death

Authors: Zhong-Die Li, Yu-Chuan Li, Jing-Zhao, Jian-She Wang, Xin-Bao Xie

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Login to get access

Abstract

Background

Clinical studies on progressive familial intrahepatic cholestasis (PFIC) type 5 caused by mutations in NR1H4 are limited.

Methods

New patients with biallelic NR1H4 variants from our center and all patients from literature were retrospectively analyzed.

Results

Three new patients were identified to be carrying five new variants. Liver phenotypes of our patients manifests as low-γ-glutamyl transferase cholestasis, liver failure and related complications. One patient underwent liver transplantation (LT) and survived, and two other patients died without LT. Nine other patients were collected through literature review. Twelve out of 13 patients showed neonatal jaundice, with the median age of onset being 7 days after birth. Reported clinical manifestations included cholestasis (13/13, 100%), elevated AFP (11/11, 100%), coagulopathy (11/11, 100%), hypoglycemia (9/13, 69%), failure to thrive (8/13, 62%), splenomegaly (7/13, 54%), hyperammonemia (7/13, 54%), and hepatomegaly (6/13, 46%). Six of 13 patients received LT at a median age of 6.2 months, and only one patient died of acute infection at one year after LT. Other 7 patients had no LT and died with a median age of 5 months (range 1.2-8). There were 8 patients with homozygous genotype and 5 patients with compound heterozygous genotype. In total, 13 different variants were detected, and 5 out of 12 single or multiple nucleotides variants were located in exon 5.

Conclusions

We identified three newly-diagnosed patients and five novel mutations. NR1H4-related PFIC typically cause progressive disease and early death. LT may be the only lifesaving therapy leading to cure.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sticova E, Jirsa M, Pawlowska J. New insights in genetic cholestasis: from molecular mechanisms to clinical implications. Can J Gastroenterol Hepatol. 2018; 2018:2313675. Sticova E, Jirsa M, Pawlowska J. New insights in genetic cholestasis: from molecular mechanisms to clinical implications. Can J Gastroenterol Hepatol. 2018; 2018:2313675.
2.
go back to reference Amirneni S, Haep N, Gad MA, Soto-Gutierrez A, Squires JE, Florentino RM. Molecular overview of progressive familial intrahepatic cholestasis. World J Gastroenterol. 2020;26:7470–84.CrossRefPubMedPubMedCentral Amirneni S, Haep N, Gad MA, Soto-Gutierrez A, Squires JE, Florentino RM. Molecular overview of progressive familial intrahepatic cholestasis. World J Gastroenterol. 2020;26:7470–84.CrossRefPubMedPubMedCentral
3.
go back to reference Vitale G, Gitto S, Vukotic R, Raimondi F, Andreone P. Familial intrahepatic cholestasis: new and wide perspectives. Dig Liver Dis. 2019;51:922–33.CrossRefPubMed Vitale G, Gitto S, Vukotic R, Raimondi F, Andreone P. Familial intrahepatic cholestasis: new and wide perspectives. Dig Liver Dis. 2019;51:922–33.CrossRefPubMed
4.
go back to reference Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim MS, Kim KH, et al. Mutations in the nuclear bile acid receptor fxr cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7:10713.CrossRefPubMedPubMedCentral Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim MS, Kim KH, et al. Mutations in the nuclear bile acid receptor fxr cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7:10713.CrossRefPubMedPubMedCentral
5.
go back to reference Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, et al. Mutations in tjp2 cause progressive cholestatic liver disease. Nat Genet. 2014;46:326–8.CrossRefPubMedPubMedCentral Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, et al. Mutations in tjp2 cause progressive cholestatic liver disease. Nat Genet. 2014;46:326–8.CrossRefPubMedPubMedCentral
6.
go back to reference Qiu YL, Gong JY, Feng JY, Wang RX, Han J, Liu T, et al. Defects in myosin vb are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis. Hepatology. 2017;65:1655–69.CrossRefPubMed Qiu YL, Gong JY, Feng JY, Wang RX, Han J, Liu T, et al. Defects in myosin vb are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis. Hepatology. 2017;65:1655–69.CrossRefPubMed
7.
go back to reference Cariello M, Piccinin E, Garcia-Irigoyen O, Sabba C, Moschetta A. Nuclear receptor fxr, bile acids and liver damage: introducing the progressive familial intrahepatic cholestasis with fxr mutations. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1308–18.CrossRefPubMed Cariello M, Piccinin E, Garcia-Irigoyen O, Sabba C, Moschetta A. Nuclear receptor fxr, bile acids and liver damage: introducing the progressive familial intrahepatic cholestasis with fxr mutations. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1308–18.CrossRefPubMed
8.
go back to reference Himes RW, Mojarrad M, Eslahi A, Finegold MJ, Maroofian R, Moore DD. Nr1h4-related progressive familial intrahepatic cholestasis 5: further evidence for rapidly progressive liver failure. J Pediatr Gastroenterol Nutr. 2020;70:e111–3.CrossRefPubMed Himes RW, Mojarrad M, Eslahi A, Finegold MJ, Maroofian R, Moore DD. Nr1h4-related progressive familial intrahepatic cholestasis 5: further evidence for rapidly progressive liver failure. J Pediatr Gastroenterol Nutr. 2020;70:e111–3.CrossRefPubMed
9.
go back to reference Czubkowski P, Thompson RJ, Jankowska I, Knisely AS, Finegold M, Parsons P, et al. Progressive familial intrahepatic cholestasis - farnesoid x receptor deficiency due to nr1h4 mutation: a case report. World J Clin Cases. 2021;9:3631–6.CrossRefPubMedPubMedCentral Czubkowski P, Thompson RJ, Jankowska I, Knisely AS, Finegold M, Parsons P, et al. Progressive familial intrahepatic cholestasis - farnesoid x receptor deficiency due to nr1h4 mutation: a case report. World J Clin Cases. 2021;9:3631–6.CrossRefPubMedPubMedCentral
10.
go back to reference Chen HL, Li HY, Wu JF, Wu SH, Chen HL, Yang YH, et al. Panel-based next-generation sequencing for the diagnosis of cholestatic genetic liver diseases: clinical utility and challenges. J Pediatr. 2019;205:153–9.CrossRefPubMed Chen HL, Li HY, Wu JF, Wu SH, Chen HL, Yang YH, et al. Panel-based next-generation sequencing for the diagnosis of cholestatic genetic liver diseases: clinical utility and challenges. J Pediatr. 2019;205:153–9.CrossRefPubMed
11.
go back to reference Yang L, Kong Y, Dong X, Hu L, Lin Y, Chen X, et al. Clinical and genetic spectrum of a large cohort of children with epilepsy in China. Genet Med. 2019;21:564–71.CrossRefPubMed Yang L, Kong Y, Dong X, Hu L, Lin Y, Chen X, et al. Clinical and genetic spectrum of a large cohort of children with epilepsy in China. Genet Med. 2019;21:564–71.CrossRefPubMed
12.
go back to reference Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17:405–24.CrossRefPubMedPubMedCentral Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17:405–24.CrossRefPubMedPubMedCentral
14.
go back to reference Rausch M, Samodelov SL, Visentin M, Kullak-Ublick GA. The farnesoid x receptor as a master regulator of hepatotoxicity. Int J Mol Sci 2022;23. Rausch M, Samodelov SL, Visentin M, Kullak-Ublick GA. The farnesoid x receptor as a master regulator of hepatotoxicity. Int J Mol Sci 2022;23.
15.
go back to reference Keitel V, Droge C, Haussinger D. Targeting fxr in cholestasis. Handb Exp Pharmacol. 2019;256:299–324.CrossRefPubMed Keitel V, Droge C, Haussinger D. Targeting fxr in cholestasis. Handb Exp Pharmacol. 2019;256:299–324.CrossRefPubMed
16.
go back to reference Hassan S, Hertel P. Overview of progressive familial intrahepatic cholestasis. Clin Liver Dis. 2022;26:371–90.CrossRefPubMed Hassan S, Hertel P. Overview of progressive familial intrahepatic cholestasis. Clin Liver Dis. 2022;26:371–90.CrossRefPubMed
17.
go back to reference Pfister ED, Droge C, Liebe R, Stalke A, Buhl N, Ballauff A, et al. Extrahepatic manifestations of progressive familial intrahepatic cholestasis syndromes: presentation of a case series and literature review. Liver Int. 2022;42:1084–96.CrossRefPubMed Pfister ED, Droge C, Liebe R, Stalke A, Buhl N, Ballauff A, et al. Extrahepatic manifestations of progressive familial intrahepatic cholestasis syndromes: presentation of a case series and literature review. Liver Int. 2022;42:1084–96.CrossRefPubMed
18.
go back to reference Yan N, Yan T, Xia Y, Hao H, Wang G, Gonzalez FJ. The pathophysiological function of non-gastrointestinal farnesoid x receptor. Pharmacol Ther. 2021;226:107867.CrossRefPubMed Yan N, Yan T, Xia Y, Hao H, Wang G, Gonzalez FJ. The pathophysiological function of non-gastrointestinal farnesoid x receptor. Pharmacol Ther. 2021;226:107867.CrossRefPubMed
19.
go back to reference Fu T, Li Y, Oh TG, Cayabyab F, He N, Tang Q, et al. Fxr mediates ilc-intrinsic responses to intestinal inflammation. Proc Natl Acad Sci U S A. 2022;119:e2081926177.CrossRef Fu T, Li Y, Oh TG, Cayabyab F, He N, Tang Q, et al. Fxr mediates ilc-intrinsic responses to intestinal inflammation. Proc Natl Acad Sci U S A. 2022;119:e2081926177.CrossRef
20.
go back to reference Xu S, Jia P, Fang Y, Jin J, Sun Z, Zhou W, et al. Nuclear farnesoid x receptor attenuates acute kidney injury through fatty acid oxidation. Kidney Int. 2022;101:987–1002.CrossRefPubMed Xu S, Jia P, Fang Y, Jin J, Sun Z, Zhou W, et al. Nuclear farnesoid x receptor attenuates acute kidney injury through fatty acid oxidation. Kidney Int. 2022;101:987–1002.CrossRefPubMed
21.
go back to reference Zheng Y, Sun W, Wang Z, Liu J, Shan C, He C et al. Activation of pancreatic acinar fxr protects against pancreatitis via osgin1-mediated restoration of efficient autophagy. Research (Wash D C). 2022; 2022:9784081. Zheng Y, Sun W, Wang Z, Liu J, Shan C, He C et al. Activation of pancreatic acinar fxr protects against pancreatitis via osgin1-mediated restoration of efficient autophagy. Research (Wash D C). 2022; 2022:9784081.
23.
go back to reference Selimoglu MA, Kaya S, Gungor S, Varol FI, Gozukara-Bag HG, Yilmaz S. Infection risk after paediatric liver transplantation. Turk J Pediatr. 2020;62:46–52.CrossRefPubMed Selimoglu MA, Kaya S, Gungor S, Varol FI, Gozukara-Bag HG, Yilmaz S. Infection risk after paediatric liver transplantation. Turk J Pediatr. 2020;62:46–52.CrossRefPubMed
24.
25.
go back to reference Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the dna binding specificity and potential target genes for the farnesoid x-activated receptor. J Biol Chem. 2000;275:10638–47.CrossRefPubMed Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the dna binding specificity and potential target genes for the farnesoid x-activated receptor. J Biol Chem. 2000;275:10638–47.CrossRefPubMed
Metadata
Title
NR1H4 disease: rapidly progressing neonatal intrahepatic cholestasis and early death
Authors
Zhong-Die Li
Yu-Chuan Li
Jing-Zhao
Jian-She Wang
Xin-Bao Xie
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-024-03166-1

Other articles of this Issue 1/2024

Orphanet Journal of Rare Diseases 1/2024 Go to the issue